The etiology of liver damage imparts cytokines transforming growth factor β1 or interleukin‐13 as driving forces in fibrogenesis

@article{Weng2009TheEO,
  title={The etiology of liver damage imparts cytokines transforming growth factor $\beta$1 or interleukin‐13 as driving forces in fibrogenesis},
  author={Honglei Weng and Yan Liu and Jia-lin Chen and Tong Huang and Li-jun Xu and Patricio Godoy and Jun Hu and Cheng Zhou and Felix Stickel and Alexander Marx and Rainer Bohle and Vincent Zimmer and Frank Lammert and Sebastian Mueller and Michelle Gigou and Didier Samuel and Peter R. Mertens and Manfred Vincenz Singer and Helmut Karl Seitz and Steven Dooley},
  journal={Hepatology},
  year={2009},
  volume={50}
}
It is unknown whether transforming growth factor β1 (TGF‐β1) signaling uniformly participates in fibrogenic chronic liver diseases, irrespective of the underlying origin, or if other cytokines such as interleukin (IL)‐13 share in fibrogenesis (e.g., due to regulatory effects on type I pro‐collagen expression). TGF‐β1 signaling events were scored in 396 liver tissue samples from patients with diverse chronic liver diseases, including hepatitis B virus (HBV), hepatitis C virus (HCV), Schistosoma… Expand
Clinico-Pathological Importance of TGF-β/Phospho-Smad Signaling during Human Hepatic Fibrocarcinogenesis
TLDR
This review addresses TGF-β/Smad signal transduction in chronic liver injuries and carcinogenic processes and discusses the reversibility of Smad signaling after antiviral therapy. Expand
Molecular Mechanism and Treatment of Viral Hepatitis-Related Liver Fibrosis
TLDR
Growing evidence has indicated that persistent viral suppression with antiviral therapy can result in fibrosis regression, reduced liver disease progression, decreased hepatocellular carcinoma, and improved chances of survival. Expand
Intricate role of yes‐associated protein1 in human liver cirrhosis: TGF‐β1 still is a giant player
TLDR
It seems that, unlike the TGF‐β1 and SHH pathways, the YAP1 pathway does not play a significant role in the development of liver cirrhosis. Expand
Clinical value of transforming growth factor beta as a marker of Fibrosis in adolescents with Chronic Liver Diseases
TLDR
Serum Transforming growth factor β had the ability to discriminate patients with significant fibrosis and may be useful in reducing but not replacing the need for liver biopsy. Expand
Significance of pSmad2/3 and Smad4 in hepatitis C virus‐related liver fibrosis and hepatocellular carcinoma
TLDR
Hematic expression of pSmad2/3 and Smad4 in CHC with different stages of fibrosis and grades of necro‐inflammation as well as in HCC on top of CHC is assessed. Expand
Histological and biochemical evaluation of transforming growth factor-β activation and its clinical significance in patients with chronic liver disease
TLDR
It is suggested that PLK-dependent TGF-β activation occurs in the early stages of fibrosis and that its unique surrogate markers, R58 and L59/LAP-DPs, are useful for monitoring the clinical course of CLD. Expand
IL-13 Signaling in Liver Fibrogenesis
TLDR
The potential roles of IL- 13 in chronic liver disease of different etiologies, and the downstream events mediating IL-13 signaling in liver fibrogenesis are summarized. Expand
Differential Regulation of TGF-β/Smad Signaling in Hepatic Stellate Cells between Acute and Chronic Liver Injuries
TLDR
This review will discuss the differential regulation of TGF-β signaling between HSC and MFB in vitro and in vivo, and the lack of Smad7 induction might lead to constitutive fibrogenesis in MFB, which eventually develop into accelerated liver fibrosis. Expand
TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis: Updated
TLDR
The present review builds on knowledge of the last two decades about TGF-β function in myofibroblast generation and fibrogenesis, and presents the milestone discoveries from the recent 3–5 years, which include findings on downstream targets with fibrogenic function, pathways that facilitate T GF-β expression in HSC, and miRNAs regulated by or regulating the TDF-β pathway. Expand
Inhibiting TGF-β signaling in hepatocellular carcinoma.
TLDR
A review of a number of TGF-β inhibitors, most of which are still in a preclinical stage of development, but may soon be available for trial in HCC patients, and their prospects for pharmacological treatment strategies. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
Hepatitis C virus core protein upregulates transforming growth factor‐β1 transcription
TLDR
The results suggest that the HCV core protein expression may upregulate directly TGF‐β1 transcription in parenchymal cells and suggest a new paradigm for exacerbation of liver fibrosis by HCV infection. Expand
Progression of fibrosis in hepatitis C with and without schistosomiasis: Correlation with serum markers of fibrosis
TLDR
In conclusion, serial cytokine and fibrosis markers can accurately determine the rate at which fibrosis is progressing, identifying both those with rapid fibrosis and those with stable disease. Expand
Modulation of the Transforming Growth Factor-β Signal Transduction Pathway by Hepatitis C Virus Nonstructural 5A Protein*
TLDR
Results indicate that HCV NS5A modulates TGF-β signaling through interaction with TβR-I and that NS5a may be an important risk factor in HCV-associated liver pathogenesis. Expand
IL-13 Activates a Mechanism of Tissue Fibrosis That Is Completely TGF-β Independent
TLDR
Several genes, including interstitial collagens, several MMPs, and tissue inhibitors of metalloprotease-1 were up-regulated in TGF-β1−/− mice by IL-13, demonstrating thatIL-13 activates the fibrogenic machinery directly. Expand
Quantitative analysis of transforming growth factor β1 messenger RNA in the liver of patients with chronic hepatitis C: Absence of correlation between high levels and severity of disease
TLDR
Data from a new competitive reverse gene amplification assay are consistent with the hypothesis that TGFβ1 plays a role in stimulating liver fibrogenesis during chronic HCV, despite the lack of prognostic value of TGF β1 mRNA levels measured before treatment. Expand
Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor β signaling, promoting cirrhosis and hepatocellular carcinoma
TLDR
Results indicate that chronic inflammation associated with HCV infection shifts hepatocytic TGF‐β signaling from tumor‐suppression to fibrogenesis, accelerating liver fibrosis and increasing risk for HCC. Expand
Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription.
TLDR
The results suggest that the HCV core protein expression may upregulate directly TGF-beta 1 transcription in parenchymal cells and suggest a new paradigm for exacerbation of liver fibrosis by HCV infection. Expand
Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells.
TLDR
A direct interaction between HCV proteins and HSCs may contribute to HCV-induced liver fibrosis, and HCV core and nonstructural proteins regulate distinct biologic functions in H SCs. Expand
The hepatitis B virus encoded oncoprotein pX amplifies TGF-beta family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis.
TLDR
PX enhances transcriptional activity in response to TGF-beta, BMP-2, and activin by stabilizing the complex of Smad4 with components of the basic transcriptional machinery, and suggests that enhanced Smad-mediated signaling may contribute to HBV-associated liver fibrosis. Expand
TGF-β/Smad signaling in the injured liver
TLDR
This review summarizes the knowledge about TGF-beta signal transduction in HSCs with special impact on Smad pathways and introduces hepatocyte plasticity and epithelial-to-mesenchymal transition in the liver as a potential feature of fibrogenesis and highlights possible action points of T GF-beta in these contexts. Expand
...
1
2
3
4
5
...